GSK publishes Q3 2026 results infographic
Bitget2026/10/28 07:20- GSK reported Q3 2026 sales of £8.9 billion, up 5%; core operating profit rose 5% to £3.1 billion.
- Specialty Medicines sales increased 15% to £3.9 billion; vaccine sales fell 2% to £2.6 billion.
- General Medicines sales held steady at £2.4 billion; total earnings per share fell 21% to 38.5p.
- Core earnings per share rose 1% to 54.6p; the dividend was 17p per share.
- Hibsago secured US and Japanese approvals; US regulators also cleared Jemperli for rectal cancer and Jideytro for lung cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lyft (LYFT.US) plans to significantly expand its Waymo autonomous taxi fleet in Nashville by the end of the year
Lyft plans to expand its fleet of Waymo driverless taxis in Nashville by the end of the year.
Japanese stocks fall below 57,000 points
Texas Governor-Elect: Data centers must be suspended until measures to protect the interests of the people are introduced
The newly elected governor of Texas, Hinojosa, publicly stated that she despises the way data centers "take advantage of Texans" and that any measures must be paused before the introduction of new data centers. She also expressed willingness to collaborate with tech giants such as Elon Musk but emphasized that "it must be on our terms." Goldman Sachs previously warned that the current "blue wave" could result in a suspension order affecting the expansion capacity of approximately 45% of data centers across the United States, with Texas accounting for about 25%. Other states are also rushing to follow Texas' lead.
DIFC Court proposes establishing an oracle to enforce tokenized asset court rulings
Crypto prices
More
